Kerry Anne Rye

Ph.D – University of New South Wales – Australia

Kerry-Anne Rye

Go further with Kerry-Anne Rye’s video interviews below

Kerry-Anne Rye obtained her PhD from The Flinders University of South Australia in 1986 and gained her postdoctoral training at The University of Illinois at Urbana Champaign. She is a Research Professor and director of the Lipid Research Group, University of New South Wales and Head of Mechanisms of Disease and Translational Research in the Department of Pathology. She is an Associate Editor of the Journal of Lipid Research, and an Editorial Board Member of three American Heart Association journals: Arteriosclerosis, Thrombosis and Vascular Biology; The Journal of the American Heart Association and Circulation Research. Professor Rye is the past Chair of the American Heart Association ATVB Council Women’s Leadership Committee, a member of the ATVB Leadership and International Mentoring Committees, Chair of the Program Committee (ATVB Council nominee) for American Heart Association Scientific Sessions  and runs a mentoring program for early career members of the ATVB Council.

Professor Rye studies high density lipoprotein (HDL) structure, function and metabolism. She was the first to report that, in addition to reducing cardiovascular risk, HDLs are anti-inflammatory and increase insulin synthesis and secretion in pancreatic beta cells. Her research program also involves elucidation of the signal transduction pathways responsible for these effects, with a view to identifying new therapeutic targets. She has developed several novel animal models and imaging techniques for use in these studies.

Source : UNSW Australia

Go further with Kerry-Anne Rye

How HDL may participate in lesion progression, plaque stability, and acute coronary syndromes?

Could you summarize some of the data you presented on HDL, Beta cells, Insulin secretion and diabetes ?

 What mechanisms might be involved in insulin sensitivity

 Do you have data on ApoA1 infusions in animals and insulin sensitivity?

Is there a role for looking at the HDL in the diabetic patient?